27 May 2008
Microgen plc (the "Company")
Notifiable Interests
Following the Company's recent announcement of an increase in its issued share
capital to 102,899,776 Ordinary Shares, the Company received notice on 23 May
2008 in compliance with the Disclosure and Transparency Rules that Aberforth
Partners LLP that its holding of 19,391,277 Ordinary Shares now represents
18.84% of the issued share capital of the Company.
Aberforth Partners is interested in 16,530,477 of the voting rights of these
Ordinary Shares representing 16.06% of the issued share capital of the Company.
The shares are registered in the name of:
No. of shares
Aberforth Smaller Companies Trust plc 7,721,426
(Nortrust Nominees Ltd A/c Aberfrth)
Aberforth UK Small Companies Fund 6,169,351
(Nortrust Nominees Ltd A/c Aberfrth)
The Church Commissioners for England 1,328,200
(The Church Commissioners for England (Chase GIS) Nominees
Ltd
Aberforth Geared Capital & Income Trust plc 1,311,500
If you require further information please contact:
G.E. Liddle, Company Secretary Tel: 01252 772 313
www.microgen.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.